In studies of 1,537 adults previously treated with other anti-epileptic drugs, 23% stopped oxcarbazepine due to adverse reactions. Dizziness topped the list at 6.4%, followed by diplopia at 5.9%, ataxia at 5.2%, vomiting at 5.1% and nausea at 4.9%, the records state. Somnolence, headache, fatigue, abnormal vision, tremor, abnormal gait, rash and hyponatremia each led to discontinuation rates from 3.8% down to 1%.

Adults new to anti-epileptic drugs fared better, with 9% of 295 patients dropping out. Dizziness, nausea, rash and headache each hit 1.7% or 1.4% in that group.

Pediatric patients aged 4 and older mirrored adult patterns. Among 456 children previously on other drugs, 11% quit, mainly from somnolence at 2.4%, vomiting at 2%, ataxia at 1.8% and others around 1%. In 152 untreated kids that age, 9.2% discontinued, with rash at 5.3% and maculopapular rash at 1.3% most common.

Younger children, from 1 month to under 4 years, saw 11% of 241 patients stop treatment. Convulsions caused 3.7% of dropouts, status epilepticus 1.2% and ataxia 1.2%. Infections appeared more often in this group than in older patients.

Controlled trials highlighted dose-related issues. Table 3 from adjunctive therapy studies in adults listed reactions hitting at least 2% of oxcarbazepine patients versus placebo. Dizziness, somnolence, ataxia, nausea and others exceeded placebo rates at various doses.

In monotherapy conversion trials, high-dose oxcarbazepine at 2,400 mg daily doubled some side effects compared to 300 mg. Adults switching from other drugs reported higher nausea, dizziness and diplopia on the higher dose, per Table 4.

A study of untreated adults, outlined in Table 5, showed similar trends. Headache, nausea, dizziness and viral infection each affected at least 2% more on oxcarbazepine than placebo.

Pediatric adjunctive or monotherapy data in Table 6 confirmed somnolence, vomiting, diplopia, ataxia, dizziness, fatigue and nystagmus as standout issues in kids previously treated with other drugs.

Beyond common reactions, oxcarbazepine linked to rarer events in 565 children and 1,574 adults. Body-wide effects included fever, malaise and weight loss. Cardiovascular reports noted bradycardia, hypertension and syncope. Digestive issues ranged from dry mouth and flatulence to ulcers and bleeding.

Hematologic changes featured thrombocytopenia. Lab abnormalities showed elevated liver enzymes, hyperglycemia and electrolyte shifts. Nervous system reactions spanned anxiety, amnesia, convulsions and psychosis. Skin problems included rashes, alopecia and angioedema. Respiratory effects covered asthma and dyspnea.

The data warns of Drug Reaction with Eosinophilia and Systemic Symptoms, a multi-organ hypersensitivity risk. Trial rates may not match real-world use, as conditions vary widely, according to the report.